Clicky

Palisade Bio, Inc.(PALI)

Description: Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.


Keywords: Medicine Surgery Digestive System Abdominal Pain Gastrointestinal Tract Adhesion Feces Investigational Therapies

Home Page: www.palisadebio.com

PALI Technical Analysis

5800 Armada Drive
Carlsbad, CA 92008
United States
Phone: 858 704 4900


Officers

Name Title
Mr. J. D. Finley Interim CEO & CFO
Ms. Sharon McBrayer Director of Operations
Mr. Robert C. McRae Sr. VP of Operations & Strategic Devel.
Dr. Herbert B. Slade FAAAAI, M.D. Chief Medical Officer
Mr. Ryker Willie VP of Fin. & Corp. Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.2358
Price-to-Book MRQ: 0.2952
Price-to-Sales TTM: 0
IPO Date: 2006-12-20
Fiscal Year End: December
Full Time Employees: 13
Back to stocks